Clinical Trials for Prostate Cancer

A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced, nonresectable, or metastatic solid tumors—including HR+/HER2- breast cancer, platinum-resistant serous ovarian, endometrial, and other tumors with likely CDK2 dependency—who have progressed on standard therapies. Patients receive the investigational selective CDK2 inhibitor BG-68501 as monotherapy or in combination with fulvestrant, with HR+/HER2- breast cancer patients also eligible for a triple combination with fulvestrant and the selective CDK4 inhibitor BGB-43395.

ClinicalTrials.gov ID: NCT06257264

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial enrolls adults with advanced, unresectable, or metastatic solid tumors (excluding primary CNS tumors) who have progressed on or are intolerant to standard therapies, with preferential inclusion of BRCA2 loss-of-function cases. Patients receive ETX-19477, a novel reversible small molecule inhibitor of poly(ADP-ribose) glycohydrolase (PARG), given as monotherapy.

ClinicalTrials.gov ID: NCT06395519

A Phase 1, Open-Label, Dose-Escalation and Expansion Study of AGX101, a TM4SF1 Directed Antibody Drug Conjugate in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients are adults with unresectable, locally advanced, or metastatic solid tumors who have exhausted standard therapies, good performance status (ECOG 0-1), and adequate organ function. The investigational agent is AGX101, a TM4SF1-targeted antibody-drug conjugate delivering a maytansinoid payload to tumor and tumor vasculature cells.

ClinicalTrials.gov ID: NCT06440005

A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced unresectable or metastatic solid tumors (including a broad range such as ovarian, pancreatic, GI, lung, and more) or relapsed/refractory multiple myeloma who have failed or are intolerant to standard therapies are eligible to receive QXL138AM, a masked anti-CD138 immunocytokine fused to interferon alpha-2a designed for tumor-targeted immune activation.

ClinicalTrials.gov ID: NCT06582017

A Phase I, Multicentre, Open-label, First-in-Human, Dose Escalation and Expansion Study of DM002 in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced, measurable solid tumors and assessable MUC1 and/or HER3 expression are eligible to receive DM002, a bispecific antibody-drug conjugate targeting MUC1 and HER3, given intravenously every three weeks.

ClinicalTrials.gov ID: NCT06751329

An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study With Peluntamig (PT217) Followed by a Key ChemotherapY and/or Checkpoint Inhibitor ComBination in Patients With NeuRoendocrIne Carcinomas That Are Known to be DLL3 expressinG CancErs (SKYBRIDGE)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with DLL3-expressing advanced/metastatic neuroendocrine carcinomas (including SCLC, LCNEC, and extrapulmonary NEC; predominant ≥50% neuroendocrine component) receive peluntamig (PT217), a bispecific anti-DLL3/CD47 IgG designed to promote macrophage phagocytosis and ADCC, as monotherapy or combined with carboplatin/etoposide, paclitaxel, and/or atezolizumab. Cohorts include relapsed/refractory disease and line-specific settings such as platinum-sensitive second line and ES-SCLC first-line or post-induction with atezolizumab.

ClinicalTrials.gov ID: NCT05652686

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling adults with metastatic rare genitourinary cancers across multiple histologic cohorts (e.g., small cell/neuroendocrine bladder, variant urothelial, penile, sarcomatoid/unclassified RCC, collecting duct, renal medullary, urethral; including a bone-only GU cohort), with up to two prior lines allowed (cohort-specific exceptions. Patients receive cabozantinib (MET/VEGFR2/AXL multi-kinase inhibitor) plus nivolumab (PD-1) and ipilimumab (CTLA-4) for up to 2 years.

ClinicalTrials.gov ID: NCT03866382

A Phase I Clinical Trial of an Infusion of Autologous Gamma Delta T Cells Genetically Engineered With a Chimeric Receptor to Target the Prostate Stem Cell Antigen in Patients With Metastatic Castration Resistant Prostate Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Men with metastatic castration‑resistant prostate cancer predominantly to bone, previously treated with at least one taxane (or other chemotherapy) and one AR‑targeted agent, receive lymphodepletion (fludarabine/cyclophosphamide) followed by a single infusion of autologous γδ T cells engineered with a PSCA‑targeted CAR (CD28/CD3ζ), with protocol‑directed zoledronic acid to support γδ T‑cell activation and bone health. Single‑center, open‑label dose escalation/expansion; key exclusions include active viral infections, significant cardiac/autoimmune disease, unstable CNS metastases, and contraindication to zoledronic acid.

ClinicalTrials.gov ID: NCT06193486

An Open-label, Multicentre, Integrated Phase 1 & 2 Study to Evaluate the Safety, Tolerability, Radiation Dosimetry and Anti-tumour Activity of Lutetium (177Lu) rhPSMA-10.1 Injection in Men With Metastatic Castrate-resistant Prostate Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Men with PSMA-positive metastatic castration-resistant prostate cancer: Phase 1 enrolls post-NAAD and after 1–2 taxane lines; Phase 2 enrolls post-NAAD without prior mCRPC taxanes. Investigational therapy is 177Lu-rhPSMA-10.1, a PSMA-targeted beta-emitting radioligand delivering lutetium-177 to tumor cells, given in various fixed-activity dosing regimens to define safety, dosimetry, and PSA response.

ClinicalTrials.gov ID: NCT05413850

An Open-label, Phase 1 Study of DCC-2812 Monotherapy in Participants With Advanced or Metastatic Renal Cell Carcinoma, Urothelial Cancer, or Castration-Resistant Prostate Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with advanced or metastatic renal cell carcinoma, urothelial carcinoma, or castration-resistant prostate cancer receive oral DCC-2812 monotherapy, a first-in-human, selective GCN2 activator that engages the integrated stress response (eIF2α phosphorylation/ATF4) to disrupt tumor survival pathways. Dose-escalation evaluates safety, dose-limiting toxicities, and PK, with preliminary antitumor activity assessed.

ClinicalTrials.gov ID: NCT06966024